Avexitide for Treatment of Post-Bariatric Hypoglycemia
← catalyst calendarSponsored by Amylyx Pharmaceuticals Inc. (industry) · AMLX — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
75estimated
Sites
21
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-29 | actual | When the study began enrolling |
| Primary completion | Mar 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Post Bariatric Hypoglycemia
Interventions
- Drug: Avexitide — also filed as exendin 9-39
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFComposite rate of Level 2 and Level 3 hypoglycemic events
measured During the double-blind treatment period (approximately 16 weeks)
Safety and Tolerability of avexitide
measured During the double-blind treatment period (approximately 16 weeks)
Incidence of anti-drug antibodies (ADAb)
measured During the double-blind treatment period (approximately 16 weeks)
Permalink · AMLX's whole pipeline · Catalyst calendar · Every registered study · What changed